AirSculpt Technologies, Inc. (AIRS) - 10-Q Summary
Business Context and Reporting Period
Company: AirSculpt Technologies, Inc.
Reporting Period: Quarter and six months ended June 30, 2026.
Business Model: Provider of practice management services to professional associations offering minimally invasive liposuction (AirSculpt®) procedures. The company operates 31 centers across 20 states and Canada as of August 2026. Revenue is 100% self-pay.
Key Financial Metrics
| Metric ($000s) | 3 Months Ended Jun 30, 2026 |
6 Months Ended Jun 30, 2026 |
6 Months Ended Jun 30, 2025 |
|---|---|---|---|
| Revenue | $42,900 | $82,289 | $83,383 |
| Net Loss | $(1,112) | $(3,509) | $(3,438) |
| Adjusted EBITDA | $4,937 | $8,248 | $9,590 |
| Adjusted EBITDA Margin | 11.5% | 10.0% | 11.5% |
| Cash & Equivalents | $18,824 | $18,824 | $8,189 |
| Total Debt (Net) | $43,568 | $43,568 | $56,045 |
| Operating Cash Flow | N/A | $4,033 | $5,852 |
Operational Metrics (6 Months): 6,458 cases performed (vs. 6,468 prior year). Revenue per case was $12,742 (vs. $12,892 prior year).
Material Changes vs. Prior Period
- Revenue Decline: Revenue decreased 2.5% QoQ and 1.3% YoY (6-month). This was driven by a ~2% decrease in average selling price on a same-center basis, partially offset by a 1.1% increase in same-center case volume. The closure of the London clinic in late 2025 also impacted prior-year comparisons.
- Expense Management: Cost of service decreased 3.7% QoQ due to personnel efficiencies. However, Selling, General, and Administrative (SG&A) expenses increased 3.3% QoQ, primarily due to a $1.4 million increase in advertising spend.
- Debt Reduction: Total debt decreased significantly from $56.0 million to $43.6 million (net) due to voluntary prepayments of $10.0 million in Q1 2026 and $10.0 million in Q2 2025.
- Liquidity Improvement: Cash and cash equivalents more than doubled to $18.8 million from $8.4 million at year-end 2025, supported by $19.6 million in net proceeds from an At-The-Market (ATM) offering.
Guidance, Outlook, Risks, and Unusual Items
- Debt Covenants & Amendments: On August 7, 2026, the company entered a "Fourth Amendment" to its Credit Agreement. This extends the maturity to November 15, 2027, but requires mandatory $5.0 million principal payments in 2026 ($2.5M upon signing, $2.5M by Sept 30). Crucially, 50% of net proceeds from future equity issuances must be used to prepay term loans.
- Internal Control Weaknesses: Management concluded disclosure controls were not effective as of June 30, 2026. Material weaknesses persist regarding general accounting processes and lease accounting (ASC 842), requiring restatement of prior financials. Remediation is ongoing but not yet complete.
- Market Risks: The company faces competition from weight-loss drugs and regulatory actions. It relies heavily on cash flow from operations and equity markets for liquidity.
- Unusual Items: The company recorded $0.3 million in litigation settlements and $1.0 million in one-time SOX compliance costs during the six months ended June 30, 2026.
Investor Verification Checklist
- Debt Service Capacity: Verify the company's ability to meet the mandatory $5.0 million debt payments required by the Fourth Amendment in late 2026 without further dilution.
- Remediation Progress: Monitor the timeline for remediation of material weaknesses in internal controls, specifically regarding lease accounting and financial reporting processes.
- Equity Dilution Impact: Assess the impact of the new covenant requiring 50% of future equity proceeds to be applied to debt repayment, which limits capital available for operations.
- Same-Center Growth: Confirm if the 1.1% same-center case volume growth can be sustained despite the 2% decline in revenue per case.
- Advertising ROI: Evaluate the return on the increased advertising spend ($16.6M for 6 months) given the overall revenue decline.